Evidence map›Paper›PMID 40969366›Full record

ArticleFrontiers in endocrinology2025

Comprehensive bioinformatics and

Yakun Yang, Xingyu He, Wei Liu, Lin Mu, Shuo Wang

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yakun Yang *Department of Pharmacology, The Key Laboratory of Neural and Vascular Biology, Ministry of Education, The Key Laboratory of New Drug Pharmacology and Toxicology, Collaborative Innovation Center of Hebei Province for Mechanism, Diagnosis and Treatment of Neuropsychiatric Diseases, Hebei Medical University, Shijiazhuang, Hebei, China.
Xingyu He *Key Laboratory of Kidney Diseases of Hebei Province, Department of Pathology, Center of Metabolic Diseases and Cancer Research, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang, Hebei, China.
Wei LiuKey Laboratory of Kidney Diseases of Hebei Province, Department of Pathology, Center of Metabolic Diseases and Cancer Research, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang, Hebei, China.
Lin MuDepartment of Nephrology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Shuo WangKey Laboratory of Kidney Diseases of Hebei Province, Department of Pathology, Center of Metabolic Diseases and Cancer Research, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetic nephropathy is a leading cause of end-stage renal disease worldwide, characterized by progressive glomerulosclerosis, chronic inflammation, and extracellular matrix (ECM) accumulation. Despite advances in clinical management, the underlying molecular mechanisms remain incompletely understood, and reliable biomarkers for early diagnosis and targeted therapy are still lacking. Methods: To identify candidate molecular genes associated with DN, we conducted an integrative bioinformatics analysis combining transcriptomic profiling, weighted gene co-expression network analysis, protein-protein interaction network construction, and machine learning-based feature selection. The biological relevance of candidate genes was validated using human renal biopsy specimens and two diabetic mouse models. Gene set enrichment analysis was performed to uncover associated functional pathways. Results: Four genes-COL1A2, CD163, FN1, and CCL2-were consistently upregulated in both human and murine DN samples. These genes are closely associated with immune activation, ECM remodeling, and chronic inflammation. GSEA revealed their significant enrichment in pathways such as NOD-like receptor signaling, ECM-receptor interaction, and T/B cell receptor signaling, highlighting their potential roles in DN pathogenesis. Experimental validation confirmed elevated expression of these genes at both mRNA and protein levels. Conclusion: Our study identifies COL1A2, CD163, FN1, and CCL2 as key molecular signatures involved in the immunoinflammatory and fibrotic progression of diabetic nephropathy. These genes hold promise as potential biomarkers and therapeutic targets, offering novel insights into the molecular mechanisms and clinical management of DN.

Indexed as

Computational BiologyDiabetic NephropathiesAnimalsAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersChemokine CCL2Diabetes Mellitus, ExperimentalDisease ProgressionFibronectinsGene Expression ProfilingHumansMaleMiceMice, Inbred C57BLReceptors, Cell SurfaceAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersCCL2 protein, humanChemokine CCL2FibronectinsFN1 protein, humanReceptors, Cell Surfacebioinformatics analysisdiabetic nephropathyinflammationkey genesmachine learning

Identifiers

PMID40969366
PMCPMC12440768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.